Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
Demonstration of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Antiplatelet Effect of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT01806077, this PHASE1 trial focuses on Coronary Artery Disease Risk Factors Multiple and Vascular Disease and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 6 times since 2013, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- Sinai Hospital of Baltimore
- Tufts Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .